Hepatitis C among people who inject drugs in Tbilisi, Georgia: An urgent need for prevention and treatment

International Journal of Drug Policy

Volumn 25, Issue 5, 2014, Pages 871-878

  Bouscaillou, Julie ^a   Champagnat, Julie ^a   Luhmann, Niklas ^a   Avril, Elisabeth ^a   Inaridze, Ina ^b   Miollany, Véronique ^b   Labartkava, Koka ^c   Kirtadze, Irma ^d   Butsashvili, Maia ^e   Kamkamidze, George ^e   Pataut, Dominique ^a  

^a République Démocratique du Congo   (France)

^b Médecins du Monde   (Georgia)

^c New Vector   (Georgia)

^d Addiction Research Center   (Georgia)

^e Clinic Neolab   (Georgia)

Author keywords

Drug users; Hepatitis C; Liver fibrosis; Respondent driven sampling; Treatment needs

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABUSE; ELASTOGRAPH; ELASTOGRAPHY; EPIDEMIC; FEMALE; HARM REDUCTION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS RAPID TEST; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; INJECTION; INTERVIEW; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; NEEDS ASSESSMENT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; VIRUS DETECTION; YOUNG ADULT; COMPLICATION; GENETICS; GENOTYPE; GEORGIA (REPUBLIC); HEALTH SERVICE; HEPACIVIRUS; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; PATHOLOGY; PREVALENCE; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STATISTICAL MODEL; SUBSTANCE ABUSE;

ADULT; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENOTYPE; GEORGIA (REPUBLIC); HARM REDUCTION; HEALTH SERVICES NEEDS AND DEMAND; HEPACIVIRUS; HEPATITIS C; HUMANS; LINEAR MODELS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84924033601     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2014.01.007     Document Type: Article

References (36)

1. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. International Journal of Drug Policy 2007, 18(October (5)):352-358.
2. Babor T.F., Higgins-Biddle J.C., Saunders J.B., Monteiro M.G. The alcohol use disorders identification test: Guidelines for use in primary care 2001, World Health Organisation, Geneva. 2nd ed.
3. Ciccozzi M., Zehender G., Cento V., Lo Presti A., Teoharov P., Pavlov I., et al. Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users. Journal of Medical Virology 2011, 83(September (9)):1565-1570.
4. Cross T.J., Calvaruso V., Maimone S., Carey I., Chang T.P., Pleguezuelo M., et al. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. Journal of Viral Hepatitis 2010, 17(August (8)):546-554.
5. Curatio International Foundation Behavioral surveillance Survey on injecting drug users in five cities of Georgia 2012.
6. Dershem L., Tabatadze M., Sirbiladze T., Tavzarashvili L., Todadze K., Tsagareli T. Characteristics, high-risk behaviors and knowledge of STI/HIV/AIDS, and prevalence of HIV, syphilis and hepatitis among injecting drug users in Batumi, Georgia: 2002-2006 2007, USAID, Washington, DC, http://pdf.usaid.gov/pdf_docs/PNADK406.pdf Accessed 18.10.13.
7. Foucher J., Reiller B., Jullien V., Léal F., di Cesare E.S., Merrouche W., et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: A prospective study. Journal of Viral Hepatitis 2009, 16(February (2)):121-131.
8. Gigi E., Sinakos E., Sykja A., Androulakis G., Tanis C., Stayridou V., et al. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. Journal of Addiction Medicine 2013, 7(January-February (1)):52-57.
9. Global Commission on Drug Policy The negative impact of the war on drugs on public health: The hidden hepatitis c epidemic 2013.
10. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases 2011, 204(July (1)):74-83.
11. Heckathorn D.D. Respondent driven sampling, a new approach to the study of hidden population. Social Problems 1997, 44(May (2)):174-198.
12. Javakhishvili D.J., Sturua L., Otiashvili D., Kirtadze I., Zabransky T. Drug situation in Georgia 2010, (Overview).
13. Johnston L.G., Sabin k Sampling hard-to-reach populations with respondent driven sampling. Methodological Innovations Online 2010, 5(2):38-48.
14. Karchava M., Sharvadze L., Gatserelia L., Badridze N., Tsertsvadze T. Prevailing HCV genotypes and subtypes among HIV infected patients in Georgia. Georgian Medical News 2009, (December (177)):51-55.
15. Kielland K.B., Delaveris G.J.M., Rogde S., Eide T.J., Amundsen E.J., Dalgard O. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study. Journal of Hepatology 2013, (Epub ahead of print).
16. Larsen C., Bousquet V., Delarocque-Astagneau E., Pioche C., Roudot-Thoraval F., HCV Surveillance Steering Committee, et al. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. Journal of Medical Virology 2010, 82(October (10)):1647-1654.
17. Moessner B.K., Jørgensen T.R., Skamling M., Vyberg M., Junker P., Pedersen C., et al. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 2011, 106(May (5)):970-976.
18. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57(April (4)):1333-1342.
19. Momenghailibaf A. Hepatitis C treatment: Price, profits, and barriers to access 2013, Open Society Foundations, NY.
20. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378(August (9791)):571-583.
21. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y., Bell B. The contributions of hepatitis B virus and hepatitis C virus to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006, 45:529-538.
22. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349(March (9055)):825-832.
23. Roy K., Hay G., Andragetti R., Taylor A., Goldberg D., Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiology and Infection 2002, 129(December (3)):577-585.
24. Sharvadze L., Nelson K.E., Imnadze P., Karchava M., Tsertsvadze T. Prevalence of HCV and genotypes distribution in general population of Georgia. Georgian Medical News 2008, (December (165)):71-77.
25. Shin W.G., Park S.H., Jun S.Y., Jung J.O., Moon J.H., Kim J.P., et al. Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases. Gut Liver 2007, 1(December (2)):145-150.
26. Sirbiladze T., Tavzarshvili L., Zabransky T., Sturua L. Estimating the prevalence of injection drug use in five cities of Georgia 2009, (Report).
27. Spiller M., Cameron C., Heckathorn D. RDSAT 7.1 user manual 2012.
28. Stvilia K., Tsertsvadze T., Sharvadze L., Aladashvili M., del Rio C., Kuniholm M.H., et al. Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: A population-based survey of the adult population of Tbilisi, Republic of Georgia. Journal of Urban Health 2006, 83(March (2)):289-298.
29. Stoové M.A., Gifford S.M., Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence 2005, 77(January (1)):81-86.
30. Tsertsvadze T., Dolmazashvili E., Abutidze A., Sharvadze L., Kachava M. Assessment of liver fibrosis and cirrhosis by transient elastography among patients with chronic HBV and HCV infection in Georgia. Georgian Medical News 2008, 12(November (165)):38-42.
31. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 2011, 106(November (11)):1978-1988.
32. World Health Organization Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia 2006, http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf Accessed 01.06.13.
33. World Health Organization Epidemiological fact sheet on HIV and AIDS, Georgia, update 2008, http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_GE.pdf Accessed 01.06.13.
34. World Health Organization Viral hepatitis resolution 2010, http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_R16-en.pdf Accessed 01.06.13.
35. World Health Organization Georgia statistics summary 2013, http://apps.who.int/gho/data/view.country.9100 Accessed 01.06.13.
36. Yilmaz Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepatitis Monthly 2011, 11(February (2)):103-106.